vitamin k 3 has been researched along with Cancer of Prostate in 9 studies
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A clinical trial with prostate cancer patients submitted to the association of ascorbic acid-menadione was performed and PSA/homocysteine was assessed in the follow- up." | 2.71 | Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer. ( Cucchi, S; Golomar, W; Gordon, W; Lasalvia-Galante, E; Lasalvia-Prisco, E; Vázquez, J, 2003) |
| "Using a mouse model of prostate cancer, the combination of α-TOS, VK3 and AA was more efficient in tumor suppression than when the drugs were given separately, without deleterious side effects." | 1.38 | Alpha-tocopheryl succinate inhibits autophagic survival of prostate cancer cells induced by vitamin K3 and ascorbate to trigger cell death. ( Alleva, R; Borghi, B; Dong, L; Garrone, B; Goodwin, J; Guerrieri, R; Manzella, N; Milanese, C; Neuzil, J; Nguyen, M; Nocchi, L; Santarelli, L; Staffolani, S; Tomasetti, M, 2012) |
| "The redox-silent vitamin E analogue alpha-tocopheryl succinate (alpha-TOS) was used in combination with VK3 and AA to evaluate their effect on prostate cancer cells." | 1.36 | alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate. ( Guerrieri, R; Neuzil, J; Santarelli, L; Staffolani, S; Strafella, E; Tomasetti, M, 2010) |
| "Quercetin alone was cytotoxic on both cell lines, but demonstrated an additional 50-percent cytotoxicity on PC-3 cells when combined with VC:VK₃." | 1.36 | The vitamin C:vitamin K3 system - enhancers and inhibitors of the anticancer effect. ( Brignall, MS; Brinton, CA; Gu, YH; Lamson, DW; Plaza, SM; Sadlon, AE, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, C | 1 |
| Song, R | 1 |
| Lu, P | 1 |
| Chen, J | 1 |
| Zhou, Y | 2 |
| Shen, G | 1 |
| Jiang, M | 1 |
| Zhang, W | 1 |
| Jiang, Y | 1 |
| Yang, J | 1 |
| Yang, C | 1 |
| Meng, F | 1 |
| Yu, B | 1 |
| Khan, M | 1 |
| Yang, H | 1 |
| Gilloteaux, J | 2 |
| Jamison, JM | 3 |
| Neal, D | 1 |
| Summers, JL | 3 |
| Tomasetti, M | 2 |
| Strafella, E | 1 |
| Staffolani, S | 2 |
| Santarelli, L | 2 |
| Neuzil, J | 2 |
| Guerrieri, R | 2 |
| Lamson, DW | 1 |
| Gu, YH | 1 |
| Plaza, SM | 1 |
| Brignall, MS | 1 |
| Brinton, CA | 1 |
| Sadlon, AE | 1 |
| Nocchi, L | 1 |
| Goodwin, J | 1 |
| Nguyen, M | 1 |
| Dong, L | 1 |
| Manzella, N | 1 |
| Milanese, C | 1 |
| Garrone, B | 1 |
| Alleva, R | 1 |
| Borghi, B | 1 |
| Lasalvia-Prisco, E | 1 |
| Cucchi, S | 1 |
| Vázquez, J | 1 |
| Lasalvia-Galante, E | 1 |
| Golomar, W | 1 |
| Gordon, W | 1 |
| Tareen, B | 1 |
| Neal, DR | 1 |
| McGuire, K | 1 |
| Gerson, L | 1 |
| Diokno, A | 1 |
2 trials available for vitamin k 3 and Cancer of Prostate
| Article | Year |
|---|---|
Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarker | 2003 |
A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy.
Topics: Administration, Oral; Aged; Ascorbic Acid; Drug Therapy, Combination; Humans; Male; Middle Aged; Pro | 2008 |
7 other studies available for vitamin k 3 and Cancer of Prostate
| Article | Year |
|---|---|
A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Hy | 2020 |
Vitamin K4 induces tumor cytotoxicity in human prostate carcinoma PC-3 cells via the mitochondria-related apoptotic pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumo | 2013 |
Synergistic antitumor cytotoxic actions of ascorbate and menadione on human prostate (DU145) cancer cells in vitro: nucleus and other injuries preceding cell death by autoschizis.
Topics: Adenocarcinoma; Ascorbic Acid; Cell Death; Cell Line, Tumor; Cell Nucleus; Cytoskeleton; Humans; Mal | 2014 |
Pro-oxidant treatment of human prostate carcinoma (DU145) induces autoschizis cell death: autophagosomes build up out of injured endomembranes and mitochondria.
Topics: Autophagy; Cell Death; Cell Line, Tumor; Cytoplasm; Humans; Lysosomes; Male; Mitochondria; Prostatic | 2014 |
alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.
Topics: alpha-Tocopherol; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Cell | 2010 |
The vitamin C:vitamin K3 system - enhancers and inhibitors of the anticancer effect.
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Cell Cycle; Cholecalciferol; Curcumin; Cytotoxin | 2010 |
Alpha-tocopheryl succinate inhibits autophagic survival of prostate cancer cells induced by vitamin K3 and ascorbate to trigger cell death.
Topics: Animals; Apoptosis Inducing Factor; Ascorbic Acid; Autophagy; Caspases; Cell Line, Tumor; Disease Pr | 2012 |